Literature DB >> 27965073

Outcomes of Endonasal and Lateral Approaches to Petroclival Meningiomas.

Maria Koutourousiou1, Juan C Fernandez-Miranda2, Francisco Vaz-Guimaraes Filho2, John R de Almeida3, Eric W Wang4, Carl H Snyderman5, Paul A Gardner6.   

Abstract

OBJECTIVE: Transpetrosal approaches for the treatment of petroclival meningiomas are often associated with substantial morbidity and long recovery. With the goal of early clinical improvement, we have used less invasive surgical approaches for petroclival meningiomas.
METHODS: We retrospectively reviewed 32 patients with petroclival meningiomas. Eleven patients (34.4%) were managed with lateral approaches (retrosigmoid or far lateral approach), 17 (53.1%) with anterior midline approaches (endoscopic endonasal approach [EEA]), and 4 (12.5%) with a combination.
RESULTS: The average Karnofsky Performance Score (KPS) at presentation was 73.8. The average postoperative KPS improved to 87.9 (P < 0.001) during short-term follow-up of 14 months (range, 1-42) and was significantly higher in primary tumors (P = 0.013), tumors <4 cm (P = 0.039), and tumors without vascular encasement (P = 0.002) but remained significant regardless of age, tumor size, or vascular encasement. The greatest benefit occurred with primary tumors, in young patients and in those who underwent nontotal resection (P < 0.001). EEA had a significantly greater potential for improved KPS (P = 0.002). Gross (n = 6) or near total (n = 9) resection was achieved in 15 of 32 cases (47%). Complications included new cranial nerve palsies affecting mainly the abducens nerve (18.7%). New lower cranial nerve palsies occurred in only 1 case (3.1%). Other complications included postoperative hydrocephalus (15.6%) and cerebrospinal fluid leak (28.1%). One patient died in the perioperative period (3.1%).
CONCLUSIONS: In the short-term, less aggressive cranial base approaches, including retrosigmoid exposures and the recently introduced EEA, are effective alternatives to transpetrosal approaches for debulking petroclival meningiomas with significant early clinical improvement and limited major surgical complications.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoscopic endonasal; Karnofsky Performance Score; Petroclival meningioma; Postoperative morbidity; Retromastoid; Retrosigmoid approach

Mesh:

Year:  2016        PMID: 27965073     DOI: 10.1016/j.wneu.2016.12.001

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  The historical perspective in approaches to the spheno-petro-clival meningiomas.

Authors:  Rafael Martínez-Pérez; Giuliano Silveira-Bertazzo; Gustavo G Rangel; Pablo Albiña; Douglas Hardesty; Ricardo L Carrau; Daniel M Prevedello
Journal:  Neurosurg Rev       Date:  2019-12-04       Impact factor: 3.042

2.  Anatomical Limits of the Endoscopic Contralateral Transmaxillary Approach to the Petrous Apex and Petroclival Region.

Authors:  João Mangussi-Gomes; João T Alves-Belo; Huy Q Truong; Gustavo F Nogueira; Eric W Wang; Juan C Fernandez-Miranda; Paul A Gardner; Carl H Snyderman
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

3.  Application of endoscopic endonasal approach in skull base surgeries: summary of 1886 cases in a single center for 10 consecutive years.

Authors:  Chuzhong Li; Haibo Zhu; Xuyi Zong; Xinsheng Wang; Songbai Gui; Peng Zhao; Chunhui Liu; Jiwei Bai; Lei Cao; Yazhuo Zhang
Journal:  Chin Neurosurg J       Date:  2020-06-04

Review 4.  Midline Skull Base Meningiomas: Transcranial and Endonasal Perspectives.

Authors:  Ciro Mastantuoni; Luigi Maria Cavallo; Felice Esposito; Elena d'Avella; Oreste de Divitiis; Teresa Somma; Andrea Bocchino; Gianluca Lorenzo Fabozzi; Paolo Cappabianca; Domenico Solari
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

5.  Petroclival Meningioma: Management Strategy and Results in 21st Century.

Authors:  Vivek Kumar Kankane; Basant Kumar Misra
Journal:  Asian J Neurosurg       Date:  2021-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.